EuroBiotech: More Articles of Note


> Avacta committed to moving its tumor microenvironment activated drug conjugate into the clinic ahead of schedule. Testing in humans is due to start next year. Statement   

> Themis Bioscience secured up to $21 million (€19 million) in non-dilutive funding to support a phase 3 trial of its Chikungunya vaccine. Filings to start the trial are planned for later this year. Release  

> Merck KGaA published interim data from a phase 2 trial of tepotinib in non-small cell lung cancer. The trial linked the MET kinase inhibitor to a response rate of around 50%. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sotio’s autologous immunotherapy achieved a 15.5 month overall survival in stage 4 non-small cell lung cancer, as compared to 11.8 months in the control arm. Release 

> BerGenBio presented updated data from a trial of bemcentinib and low-intensity chemotherapy in elderly acute myeloid leukemia patients. About half of the subjects responded to the regimen. Statement   

> Corbin Therapeutics licensed neuroinflammation assets from the University of Dundee Drug Discovery Unit. Release  

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.